STOCK TITAN

[SCHEDULE 13D/A] Brainsway Ltd. American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Alpha Teknova, Inc. (TKNO) – Form 4 insider transaction

Director Martha J. Demski reported a single open-market sale of the company’s common stock on 27 June 2025. The transaction was executed under a Rule 10b5-1 trading plan adopted 12 March 2025 and was expressly intended to cover tax obligations arising from the vesting of director restricted stock units.

  • Securities sold: 8,000 common shares
  • Sale price: $5.064 per share
  • Gross proceeds: approximately $40,512
  • Post-transaction ownership: 12,000 common shares held directly

No derivative securities were acquired or disposed of, and no other transactions were reported. After the sale, Demski retains a direct equity interest in the company, but her share count declined by 40% from 20,000 to 12,000 shares. Because the disposition was pre-programmed under a 10b5-1 plan and earmarked for tax withholding, it is generally viewed as administrative rather than indicative of a changed outlook. Nevertheless, investors often monitor insider sales—especially by board members—for potential signaling effects. The filing does not disclose any changes to Demski’s role, company strategy, or financial performance.

Alpha Teknova, Inc. (TKNO) – Transazione interna Form 4

La direttrice Martha J. Demski ha segnalato una singola vendita sul mercato aperto di azioni ordinarie della società il 27 giugno 2025. L'operazione è stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 12 marzo 2025 ed è stata espressamente finalizzata a coprire obblighi fiscali derivanti dalla maturazione delle unità azionarie vincolate del direttore.

  • Azioni vendute: 8.000 azioni ordinarie
  • Prezzo di vendita: 5,064 $ per azione
  • Proventi lordi: circa 40.512 $
  • Detenzione post-transazione: 12.000 azioni ordinarie detenute direttamente

Non sono stati acquisiti o ceduti titoli derivati e non sono state riportate altre transazioni. Dopo la vendita, Demski mantiene una partecipazione azionaria diretta nella società, ma il numero delle sue azioni è diminuito del 40%, da 20.000 a 12.000 azioni. Poiché la cessione è stata preprogrammata nell'ambito di un piano 10b5-1 e destinata alla copertura fiscale, viene generalmente considerata un'operazione amministrativa piuttosto che un segnale di cambiamento di prospettiva. Tuttavia, gli investitori monitorano spesso le vendite interne, soprattutto da parte dei membri del consiglio, per possibili effetti di segnalazione. Il documento non evidenzia modifiche nel ruolo di Demski, nella strategia aziendale o nelle performance finanziarie.

Alpha Teknova, Inc. (TKNO) – Transacción interna Formulario 4

La directora Martha J. Demski reportó una única venta en el mercado abierto de acciones ordinarias de la compañía el 27 de junio de 2025. La transacción se llevó a cabo bajo un plan de negociación Rule 10b5-1 adoptado el 12 de marzo de 2025 y fue expresamente destinada a cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones del director.

  • Valores vendidos: 8,000 acciones ordinarias
  • Precio de venta: $5.064 por acción
  • Ingresos brutos: aproximadamente $40,512
  • Propiedad post-transacción: 12,000 acciones ordinarias en propiedad directa

No se adquirieron ni dispusieron valores derivados, y no se reportaron otras transacciones. Tras la venta, Demski conserva una participación directa en la compañía, pero su cantidad de acciones disminuyó un 40%, de 20,000 a 12,000 acciones. Debido a que la disposición fue preprogramada bajo un plan 10b5-1 y destinada a retención fiscal, generalmente se considera administrativa y no indicativa de un cambio de perspectiva. Sin embargo, los inversores suelen vigilar las ventas internas, especialmente de miembros del consejo, por posibles efectos de señalización. El informe no revela cambios en el rol de Demski, la estrategia de la compañía o el desempeño financiero.

Alpha Teknova, Inc. (TKNO) – Form 4 내부자 거래

이사 Martha J. Demski2025년 6월 27일 회사 보통주를 단일 공개 시장에서 매도했다고 보고했습니다. 이 거래는 2025년 3월 12일 채택된 Rule 10b5-1 거래 계획에 따라 실행되었으며, 이사 제한 주식 단위의 취득에 따른 세금 의무를 충당하기 위한 목적이 명확히 밝혀졌습니다.

  • 매도한 증권: 보통주 8,000주
  • 매도가격: 주당 $5.064
  • 총 수익: 약 $40,512
  • 거래 후 보유량: 직접 보유한 보통주 12,000주

파생 증권의 취득 또는 처분은 없었으며, 다른 거래도 보고되지 않았습니다. 매도 후 Demski는 회사에 대한 직접 지분을 유지하고 있으나, 보유 주식 수는 20,000주에서 12,000주로 40% 감소했습니다. 이 매도는 10b5-1 계획에 사전 프로그래밍되어 세금 원천징수를 위해 지정된 것이므로 일반적으로 행정적 조치로 간주되며 전망 변화의 신호로 보이지 않습니다. 그럼에도 불구하고 투자자들은 이사회 구성원의 내부자 매도를 잠재적 신호로 주시하는 경향이 있습니다. 제출된 문서에는 Demski의 역할, 회사 전략 또는 재무 성과에 대한 변경 사항이 포함되어 있지 않습니다.

Alpha Teknova, Inc. (TKNO) – Transaction d’initié Formulaire 4

La directrice Martha J. Demski a déclaré une vente unique d’actions ordinaires de la société sur le marché ouvert le 27 juin 2025. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 12 mars 2025 et visait expressément à couvrir des obligations fiscales liées à l’acquisition d’unités d’actions restreintes par la directrice.

  • Titres vendus : 8 000 actions ordinaires
  • Prix de vente : 5,064 $ par action
  • Produit brut : environ 40 512 $
  • Détention après transaction : 12 000 actions ordinaires détenues directement

Aucun titre dérivé n’a été acquis ou cédé, et aucune autre transaction n’a été signalée. Après la vente, Demski conserve une participation directe dans la société, mais son nombre d’actions a diminué de 40 %, passant de 20 000 à 12 000 actions. Étant donné que la cession a été programmée à l’avance dans le cadre d’un plan 10b5-1 et destinée à la retenue fiscale, elle est généralement considérée comme une opération administrative plutôt qu’un signe d’un changement de perspective. Néanmoins, les investisseurs surveillent souvent les ventes d’initiés – en particulier celles des membres du conseil d’administration – pour d’éventuels effets de signalisation. Le dépôt ne révèle aucun changement dans le rôle de Demski, la stratégie de l’entreprise ou la performance financière.

Alpha Teknova, Inc. (TKNO) – Insider-Transaktion Form 4

Die Direktorin Martha J. Demski meldete am 27. Juni 2025 einen einzelnen Verkauf von Stammaktien des Unternehmens am offenen Markt. Die Transaktion wurde im Rahmen eines Rule 10b5-1 Handelsplans, der am 12. März 2025 angenommen wurde, ausgeführt und diente ausdrücklich dazu, Steuerverpflichtungen aus der Zuteilung von eingeschränkten Aktienanteilen des Direktors zu begleichen.

  • Verkaufte Wertpapiere: 8.000 Stammaktien
  • Verkaufspreis: 5,064 $ pro Aktie
  • Bruttoerlös: ca. 40.512 $
  • Eigentum nach der Transaktion: 12.000 direkt gehaltene Stammaktien

Es wurden keine Derivate erworben oder veräußert, und keine weiteren Transaktionen gemeldet. Nach dem Verkauf hält Demski weiterhin eine direkte Beteiligung am Unternehmen, allerdings sank ihre Aktienanzahl um 40 % von 20.000 auf 12.000 Aktien. Da die Veräußerung vorprogrammiert im Rahmen eines 10b5-1-Plans erfolgte und zur Steuerabführung bestimmt war, wird sie allgemein als administrative Maßnahme und nicht als Hinweis auf eine geänderte Einschätzung gewertet. Dennoch beobachten Investoren Insider-Verkäufe – insbesondere von Vorstandsmitgliedern – oft auf potenzielle Signale. Die Einreichung enthält keine Hinweise auf Änderungen in Demskis Rolle, der Unternehmensstrategie oder der finanziellen Leistung.

Positive
  • Transparent 10b5-1 plan: Sale executed under a pre-adopted trading plan, enhancing disclosure and reducing potential for opportunistic trades.
Negative
  • 40% reduction in director holdings: Insider’s share count falls from 20,000 to 12,000, which may signal lower personal exposure to future upside.

Insights

TL;DR: Minor, pre-scheduled insider sale; neutral valuation impact.

The director sold 8,000 TKNO shares (40% of her stake) at $5.064 under a 10b5-1 plan to pay taxes on vested RSUs. Because the sale was predetermined and purpose-specific, it does not necessarily reflect her view of the company’s fundamentals. Remaining ownership of 12,000 shares shows continued alignment. Dollar value (~$40k) is immaterial relative to trading volume and market cap, so I view the filing as not impactful to valuation.

TL;DR: Insider sale reduces alignment; slight governance negative.

Although executed under a compliant 10b5-1 plan, the 40% reduction in holdings lessens Demski’s direct exposure to TKNO’s equity performance. Frequent or sizeable director sales can raise questions about board-level confidence. Still, continued ownership and transparent disclosure mitigate concerns. Overall governance impact is mildly negative but limited.

Alpha Teknova, Inc. (TKNO) – Transazione interna Form 4

La direttrice Martha J. Demski ha segnalato una singola vendita sul mercato aperto di azioni ordinarie della società il 27 giugno 2025. L'operazione è stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 12 marzo 2025 ed è stata espressamente finalizzata a coprire obblighi fiscali derivanti dalla maturazione delle unità azionarie vincolate del direttore.

  • Azioni vendute: 8.000 azioni ordinarie
  • Prezzo di vendita: 5,064 $ per azione
  • Proventi lordi: circa 40.512 $
  • Detenzione post-transazione: 12.000 azioni ordinarie detenute direttamente

Non sono stati acquisiti o ceduti titoli derivati e non sono state riportate altre transazioni. Dopo la vendita, Demski mantiene una partecipazione azionaria diretta nella società, ma il numero delle sue azioni è diminuito del 40%, da 20.000 a 12.000 azioni. Poiché la cessione è stata preprogrammata nell'ambito di un piano 10b5-1 e destinata alla copertura fiscale, viene generalmente considerata un'operazione amministrativa piuttosto che un segnale di cambiamento di prospettiva. Tuttavia, gli investitori monitorano spesso le vendite interne, soprattutto da parte dei membri del consiglio, per possibili effetti di segnalazione. Il documento non evidenzia modifiche nel ruolo di Demski, nella strategia aziendale o nelle performance finanziarie.

Alpha Teknova, Inc. (TKNO) – Transacción interna Formulario 4

La directora Martha J. Demski reportó una única venta en el mercado abierto de acciones ordinarias de la compañía el 27 de junio de 2025. La transacción se llevó a cabo bajo un plan de negociación Rule 10b5-1 adoptado el 12 de marzo de 2025 y fue expresamente destinada a cubrir obligaciones fiscales derivadas de la consolidación de unidades restringidas de acciones del director.

  • Valores vendidos: 8,000 acciones ordinarias
  • Precio de venta: $5.064 por acción
  • Ingresos brutos: aproximadamente $40,512
  • Propiedad post-transacción: 12,000 acciones ordinarias en propiedad directa

No se adquirieron ni dispusieron valores derivados, y no se reportaron otras transacciones. Tras la venta, Demski conserva una participación directa en la compañía, pero su cantidad de acciones disminuyó un 40%, de 20,000 a 12,000 acciones. Debido a que la disposición fue preprogramada bajo un plan 10b5-1 y destinada a retención fiscal, generalmente se considera administrativa y no indicativa de un cambio de perspectiva. Sin embargo, los inversores suelen vigilar las ventas internas, especialmente de miembros del consejo, por posibles efectos de señalización. El informe no revela cambios en el rol de Demski, la estrategia de la compañía o el desempeño financiero.

Alpha Teknova, Inc. (TKNO) – Form 4 내부자 거래

이사 Martha J. Demski2025년 6월 27일 회사 보통주를 단일 공개 시장에서 매도했다고 보고했습니다. 이 거래는 2025년 3월 12일 채택된 Rule 10b5-1 거래 계획에 따라 실행되었으며, 이사 제한 주식 단위의 취득에 따른 세금 의무를 충당하기 위한 목적이 명확히 밝혀졌습니다.

  • 매도한 증권: 보통주 8,000주
  • 매도가격: 주당 $5.064
  • 총 수익: 약 $40,512
  • 거래 후 보유량: 직접 보유한 보통주 12,000주

파생 증권의 취득 또는 처분은 없었으며, 다른 거래도 보고되지 않았습니다. 매도 후 Demski는 회사에 대한 직접 지분을 유지하고 있으나, 보유 주식 수는 20,000주에서 12,000주로 40% 감소했습니다. 이 매도는 10b5-1 계획에 사전 프로그래밍되어 세금 원천징수를 위해 지정된 것이므로 일반적으로 행정적 조치로 간주되며 전망 변화의 신호로 보이지 않습니다. 그럼에도 불구하고 투자자들은 이사회 구성원의 내부자 매도를 잠재적 신호로 주시하는 경향이 있습니다. 제출된 문서에는 Demski의 역할, 회사 전략 또는 재무 성과에 대한 변경 사항이 포함되어 있지 않습니다.

Alpha Teknova, Inc. (TKNO) – Transaction d’initié Formulaire 4

La directrice Martha J. Demski a déclaré une vente unique d’actions ordinaires de la société sur le marché ouvert le 27 juin 2025. La transaction a été réalisée dans le cadre d’un plan de négociation Rule 10b5-1 adopté le 12 mars 2025 et visait expressément à couvrir des obligations fiscales liées à l’acquisition d’unités d’actions restreintes par la directrice.

  • Titres vendus : 8 000 actions ordinaires
  • Prix de vente : 5,064 $ par action
  • Produit brut : environ 40 512 $
  • Détention après transaction : 12 000 actions ordinaires détenues directement

Aucun titre dérivé n’a été acquis ou cédé, et aucune autre transaction n’a été signalée. Après la vente, Demski conserve une participation directe dans la société, mais son nombre d’actions a diminué de 40 %, passant de 20 000 à 12 000 actions. Étant donné que la cession a été programmée à l’avance dans le cadre d’un plan 10b5-1 et destinée à la retenue fiscale, elle est généralement considérée comme une opération administrative plutôt qu’un signe d’un changement de perspective. Néanmoins, les investisseurs surveillent souvent les ventes d’initiés – en particulier celles des membres du conseil d’administration – pour d’éventuels effets de signalisation. Le dépôt ne révèle aucun changement dans le rôle de Demski, la stratégie de l’entreprise ou la performance financière.

Alpha Teknova, Inc. (TKNO) – Insider-Transaktion Form 4

Die Direktorin Martha J. Demski meldete am 27. Juni 2025 einen einzelnen Verkauf von Stammaktien des Unternehmens am offenen Markt. Die Transaktion wurde im Rahmen eines Rule 10b5-1 Handelsplans, der am 12. März 2025 angenommen wurde, ausgeführt und diente ausdrücklich dazu, Steuerverpflichtungen aus der Zuteilung von eingeschränkten Aktienanteilen des Direktors zu begleichen.

  • Verkaufte Wertpapiere: 8.000 Stammaktien
  • Verkaufspreis: 5,064 $ pro Aktie
  • Bruttoerlös: ca. 40.512 $
  • Eigentum nach der Transaktion: 12.000 direkt gehaltene Stammaktien

Es wurden keine Derivate erworben oder veräußert, und keine weiteren Transaktionen gemeldet. Nach dem Verkauf hält Demski weiterhin eine direkte Beteiligung am Unternehmen, allerdings sank ihre Aktienanzahl um 40 % von 20.000 auf 12.000 Aktien. Da die Veräußerung vorprogrammiert im Rahmen eines 10b5-1-Plans erfolgte und zur Steuerabführung bestimmt war, wird sie allgemein als administrative Maßnahme und nicht als Hinweis auf eine geänderte Einschätzung gewertet. Dennoch beobachten Investoren Insider-Verkäufe – insbesondere von Vorstandsmitgliedern – oft auf potenzielle Signale. Die Einreichung enthält keine Hinweise auf Änderungen in Demskis Rolle, der Unternehmensstrategie oder der finanziellen Leistung.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,103,745 ADSs, representing 4,207,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Aggregate amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,371,992 ADSs, representing 4,743,984 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D




Comment for Type of Reporting Person:
Aggregate amount reflects Ordinary Shares represented by ADSs, consisting of (i) 2,347,245 ADSs, representing 4,694,490 Ordinary Shares and (ii) warrants to purchase 1,500,000 ADSs, representing 3,000,000 Ordinary Shares.


SCHEDULE 13D


Valor BrainsWay Holdings, LLC
Signature:/s/ Jonathan Shulkin
Name/Title:Jonathan Shulkin, Authorized Signatory
Date:07/01/2025
Valor Siren Ventures II L.P.
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor Siren Partners II-A L.P.
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor Siren Partners II-B L.P.
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor SV Associates II L.P.
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor SV Capital II LLC
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor Management L.P.
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor Management LLC
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, CEO
Date:07/01/2025
Valor Funds Group LLC
Signature:/s/ Antonio J. Gracias
Name/Title:Antonio J. Gracias, Managing Member
Date:07/01/2025
Jonathan Shulkin
Signature:/s/Jonathan Shulkin
Name/Title:Jonathan Shulkin
Date:07/01/2025
Antonio Gracias
Signature:/s/Antonio J. Gracias
Name/Title:Antonio J. Gracias
Date:07/01/2025

FAQ

Who sold Alpha Teknova (TKNO) shares in the latest Form 4?

Director Martha J. Demski reported the transaction.

How many TKNO shares were sold and at what price?

She sold 8,000 shares at $5.064 per share.

What is Martha Demski’s remaining ownership after the sale?

She now holds 12,000 common shares directly.

Why was the sale executed?

The sale was made to cover tax obligations related to vesting RSUs and was executed under a Rule 10b5-1 plan.

When was the 10b5-1 plan adopted?

The trading plan was adopted on 12 March 2025.

Were any derivative securities involved?

No derivative securities were acquired or disposed of in this filing.
Brainsway Ltd.

NASDAQ:BWAY

BWAY Rankings

BWAY Latest News

BWAY Stock Data

247.52M
15.56M
6.42%
32.12%
0.29%
Medical Devices
Healthcare
Link
Israel
Jerusalem